Design of peptide-targeted liposomes containing nucleic acids

Biochimica et Biophysica Acta - Biomembranes

Volumn 1798, Issue 3, 2010, Pages 433-441

  Santos, Adriana O ^a,b   da Silva, Lígia C Gomes ^a,b   Bimbo, Luís M ^a,b   de Lima, Maria C Pedroso ^b,c   Simões, Sérgio ^a,b   Moreira, João N ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Antagonist G; Cancer; Liposomes; Oligodeoxynucleotide; siRNA; Targeted delivery

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; GENISTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; HEXAPEPTIDE; MACROGOL; OLIGODEOXYNUCLEOTIDE; PROTEIN BCL 2; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CONTROLLED STUDY; COVALENT BOND; CROSS COUPLING REACTION; DOWN REGULATION; ENCAPSULATION; ENDOCYTOSIS; ENDOTHELIUM CELL; GENE INSERTION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INTERNALIZATION; LIGAND BINDING; LIPID VESICLE; LIPOSOMAL DELIVERY; LUNG SMALL CELL CANCER; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN TARGETING; VASCULAR ENDOTHELIUM;

CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; FLUOROMETRY; HUMANS; LIPOSOMES; NUCLEIC ACIDS; PEPTIDES; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 76749124054     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamem.2009.12.001     Document Type: Article

References (55)

1. Stuart D.D., and Allen T.M. A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability. Biochim. Biophys. Acta 1463 (2000) 219-229
2. Semple S.C., Klimuk S.K., Harasym T.O., Dos Santos N., Ansell S.M., Wong K.F., Maurer N., Stark H., Cullis P.R., Hope M.J., and Scherrer P. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim. Biophys. Acta 1510 (2001) 152-166
3. Heyes J., Palmer L., Bremner K., and MacLachlan I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J. Control. Release 107 (2005) 276-287
4. Morrissey D.V., Lockridge J.A., Shaw L., Blanchard K., Jensen K., Breen W., Hartsough K., Machemer L., Radka S., Jadhav V., Vaish N., Zinnen S., Vargeese C., Bowman K., Shaffer C.S., Jeffs L.B., Judge A., MacLachlan I., and Polisky B. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23 (2005) 1002-1007
5. Zimmermann T.S., Lee A.C., Akinc A., Bramlage B., Bumcrot D., Fedoruk M.N., Harborth J., Heyes J.A., Jeffs L.B., John M., Judge A.D., Lam K., McClintock K., Nechev L.V., Palmer L.R., Racie T., Rohl I., Seiffert S., Shanmugam S., Sood V., Soutschek J., Toudjarska I., Wheat A.J., Yaworski E., Zedalis W., Koteliansky V., Manoharan M., Vornlocher H.P., and MacLachlan I. RNAi-mediated gene silencing in non-human primates. Nature 441 (2006) 111-114
6. Judge A.D., Robbins M., Tavakoli I., Levi J., Hu L., Fronda A., Ambegia E., McClintock K., and Maclachlan I. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J. Clin. Invest. 119 (2009) 661-673
7. Moreira J.N., Santos A., Moura V., Pedroso de Lima M.C., and Simoes S. Non-viral lipid-based nanoparticles for targeted cancer systemic gene silencing. J. Nanosci. Nanotechnol. 8 (2008) 2187-2204
8. Salon C., Merdzhanova G., Brambilla C., Brambilla E., Gazzeri S., and Eymin B. E2F-1, Skp2 and cyclin E oncoproteins are upregulated and directly correlated in high-grade neuroendocrine lung tumors. Oncogene 26 (2007) 6927-6936
9. Roelle S., Grosse R., Buech T., Chubanov V., and Gudermann T. Essential role of Pyk2 and Src kinase activation in neuropeptide-induced proliferation of small cell lung cancer cells. Oncogene 27 (2008) 1737-1748
10. Moreira J.N., Hansen C.B., Gaspar R., and Allen T.M. A growth factor antagonist as a targeting agent for sterically stabilized liposomes in human small cell lung cancer. Biochim. Biophys. Acta 1514 (2001) 303-317
11. Woll P.J., and Rozengurt E. A neuropeptide antagonist that inhibits the growth of small cell lung cancer in vitro. Cancer Res. 50 (1990) 3968-3973
12. MacKinnon A.C., Tufail-Hanif U., Wheatley M., Rossi A.G., Haslett C., Seckl M., and Sethi T. Targeting V1A-vasopressin receptors with [Arg6, D-Trp7,9, NmePhe8]-substance P (6-11) identifies a strategy to develop novel anti-cancer therapies. Br. J. Pharmacol. 156 (2009) 36-47
13. Moreira J.N., Ishida T., Gaspar R., and Allen T.M. Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity. Pharm. Res. 19 (2002) 265-269
14. Hermanson G.T. Bioconjugate techniques. 2nd ed. (2008), Academic Press
15. MacKinnon A.C., Armstrong R.A., Waters C.M., Cummings J., Smyth J.F., Haslett C., and Sethi T. [Arg6,D-Trp7,9,NmePhe8]-substance P (6-11) activates JNK and induces apoptosis in small cell lung cancer cells via an oxidant-dependent mechanism. Br. J. Cancer 80 (1999) 1026-1034
16. Keire D.A., Kumar M., Hu W., Sinnett-Smith J., and Rozengurt E. The lipid-associated 3D structure of SPA, a broad-spectrum neuropeptide antagonist with anticancer properties. Biophys. J. 91 (2006) 4478-4489
17. Ziegler A., Luedke G.H., Fabbro D., Altmann K.H., Stahel R.A., and Zangemeister-Wittke U. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J. Natl. Cancer Inst. 89 (1997) 1027-1036
18. Daleke D.L., Hong K., and Papahadjopoulos D. Endocytosis of liposomes by macrophages: binding, acidification and leakage of liposomes monitored by a new fluorescence assay. Biochim. Biophys. Acta 1024 (1990) 352-366
19. Singh R., Kats L., Blattler W.A., and Lambert J.M. Formation of N-substituted 2-iminothiolanes when amino groups in proteins and peptides are modified by 2-iminothiolane. Anal. Biochem. 236 (1996) 114-125
20. Santos A., Sarmento-Ribeiro A.B., de Lima M.C., Simoes S., and Moreira J.N. Simultaneous evaluation of viability and Bcl-2 in small-cell lung cancer. Cytometry, A 73A (2008) 1165-1172
21. Pedroso de Lima M.C., Neves S., Filipe A., Duzgunes N., and Simoes S. Cationic liposomes for gene delivery: from biophysics to biological applications. Curr. Med. Chem. 10 (2003) 1221-1231
22. Morille M., Passirani C., Vonarbourg A., Clavreul A., and Benoit J.P. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials 29 (2008) 3477-3496
23. Cardoso A.L., Simoes S., de Almeida L.P., Plesnila N., Pedroso de Lima M.C., Wagner E., and Culmsee C. Tf-lipoplexes for neuronal siRNA delivery: a promising system to mediate gene silencing in the CNS. J. Control. Release 132 (2008) 113-123
24. Faneca H., Faustino A., and Pedroso de Lima M.C. Synergistic antitumoral effect of vinblastine and HSV-Tk/GCV gene therapy mediated by albumin-associated cationic liposomes. J. Control. Release 126 (2008) 175-184
25. Neves S., Faneca H., Bertin S., Konopka K., Duzgunes N., Pierrefite-Carle V., Simoes S., and Pedroso de Lima M.C. Transferrin lipoplex-mediated suicide gene therapy of oral squamous cell carcinoma in an immunocompetent murine model and mechanisms involved in the antitumoral response. Cancer Gene Ther. 16 (2009) 91-101
26. Maurer N., Wong K.F., Stark H., Louie L., McIntosh D., Wong T., Scherrer P., Semple S.C., and Cullis P.R. Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. Biophys. J. 80 (2001) 2310-2326
27. Allen T.M., and Cullis P.R. Drug delivery systems: entering the mainstream. Science 303 (2004) 1818-1822
28. Wu N.Z., Da D., Rudoll T.L., Needham D., Whorton A.R., and Dewhirst M.W. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res. 53 (1993) 3765-3770
29. Miller C.R., Bondurant B., McLean S.D., McGovern K.A., and O'Brien D.F. Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry 37 (1998) 12875-12883
30. North W.G., Fay M.J., Longo K.A., and Du J. Expression of all known vasopressin receptor subtypes by small cell tumors implies a multifaceted role for this neuropeptide. Cancer Res. 58 (1998) 1866-1871
31. North W.G. Gene regulation of vasopressin and vasopressin receptors in cancer. Exp. Physiol. 85 Spec No (2000) 27S-40S
32. Conner S.D., and Schmid S.L. Regulated portals of entry into the cell. Nature 422 (2003) 37-44
33. Puri V., Watanabe R., Singh R.D., Dominguez M., Brown J.C., Wheatley C.L., Marks D.L., and Pagano R.E. Clathrin-dependent and -independent internalization of plasma membrane sphingolipids initiates two Golgi targeting pathways. J. Cell Biol. 154 (2001) 535-547
34. Huth U.S., Schubert R., and Peschka-Suss R. Investigating the uptake and intracellular fate of pH-sensitive liposomes by flow cytometry and spectral bio-imaging. J. Control. Release 110 (2006) 490-504
35. Mano M., Teodosio C., Paiva A., Simoes S., and Pedroso de Lima M.C. On the mechanisms of the internalization of S4(13)-PV cell-penetrating peptide. Biochem. J. 390 (2005) 603-612
36. Rejman J., Bragonzi A., and Conese M. Role of clathrin- and caveolae-mediated endocytosis in gene transfer mediated by lipo- and polyplexes. Mol. Ther. 12 (2005) 468-474
37. Wikman H., Seppanen J.K., Sarhadi V.K., Kettunen E., Salmenkivi K., Kuosma E., Vainio-Siukola K., Nagy B., Karjalainen A., Sioris T., Salo J., Hollmen J., Knuutila S., and Anttila S. Caveolins as tumour markers in lung cancer detected by combined use of cDNA and tissue microarrays. J. Pathol. 203 (2004) 584-593
38. Sunaga N., Miyajima K., Suzuki M., Sato M., White M.A., Ramirez R.D., Shay J.W., Gazdar A.F., and Minna J.D. Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res. 64 (2004) 4277-4285
39. Matkowskyj K.A., Keller K., Glover S., Kornberg L., Tran-Son-Tay R., and Benya R.V. Expression of GRP and its receptor in well-differentiated colon cancer cells correlates with the presence of focal adhesion kinase phosphorylated at tyrosines 397 and 407. J. Histochem. Cytochem. 51 (2003) 1041-1048
40. North W.G., Fay M.J., and Du J. MCF-7 breast cancer cells express normal forms of all vasopressin receptors plus an abnormal V2R. Peptides 20 (1999) 837-842
41. Martinez A., Zudaire E., Julian M., Moody T.W., and Cuttitta F. Gastrin-releasing peptide (GRP) induces angiogenesis and the specific GRP blocker 77427 inhibits tumor growth in vitro and in vivo. Oncogene 24 (2005) 4106-4113
42. Kang J., Ishola T.A., Baregamian N., Mourot J.M., Rychahou P.G., Evers B.M., and Chung D.H. Bombesin induces angiogenesis and neuroblastoma growth. Cancer. Lett. 253 (2007) 273-281
43. Cuttitta F., Carney D.N., Mulshine J., Moody T.W., Fedorko J., Fischler A., and Minna J.D. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 316 (1985) 823-826
44. Ocejo-Garcia M., Ahmed S.I., Coulson J.M., and Woll P.J. Use of RT-PCR to detect co-expression of neuropeptides and their receptors in lung cancer. Lung Cancer 33 (2001) 1-9
45. Song L.Y., Ahkong Q.F., Rong Q., Wang Z., Ansell S., Hope M.J., and Mui B. Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes. Biochim. Biophys. Acta 1558 (2002) 1-13
46. Heyes J., Hall K., Tailor V., Lenz R., and MacLachlan I. Synthesis and characterization of novel poly(ethylene glycol)-lipid conjugates suitable for use in drug delivery. J. Control. Release 112 (2006) 280-290
47. Gabrielson N.P., and Pack D.W. Efficient polyethylenimine-mediated gene delivery proceeds via a caveolar pathway in HeLa cells. J. Control. Release 136 (2009) 54-61
48. Pastorino F., Brignole C., Di Paolo D., Nico B., Pezzolo A., Marimpietri D., Pagnan G., Piccardi F., Cilli M., Longhi R., Ribatti D., Corti A., Allen T.M., and Ponzoni M. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res. 66 (2006) 10073-10082
49. Hussain S., Pluckthun A., Allen T.M., and Zangemeister-Wittke U. Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Mol. Cancer Ther. 6 (2007) 3019-3027
50. Brignole C., Pagnan G., Marimpietri D., Cosimo E., Allen T.M., Ponzoni M., and Pastorino F. Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment. Cancer Lett. 197 (2003) 231-235
51. Pastorino F., Mumbengegwi D.R., Ribatti D., Ponzoni M., and Allen T.M. Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin. J. Control. Release 126 (2008) 85-94
52. Hussain S., Pluckthun A., Allen T.M., and Zangemeister-Wittke U. Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL. Mol. Cancer Ther. 5 (2006) 3170-3180
53. Simoes S., Slepushkin V., Pretzer E., Dazin P., Gaspar R., Pedroso de Lima M.C., and Duzgunes N. Transfection of human macrophages by lipoplexes via the combined use of transferrin and pH-sensitive peptides. J. Leukoc. Biol. 65 (1999) 270-279
54. Simoes S., Slepushkin V., Pires P., Gaspar R., Pedroso de Lima M.C., and Duzgunes N. Human serum albumin enhances DNA transfection by lipoplexes and confers resistance to inhibition by serum. Biochim. Biophys. Acta 1463 (2000) 459-469
55. Simoes S., Slepushkin V., Pires P., Gaspar R., de Lima M.P., and Duzgunes N. Mechanisms of gene transfer mediated by lipoplexes associated with targeting ligands or pH-sensitive peptides. Gene Ther. 6 (1999) 1798-1807